Evidence map›Paper›PMID 31721100›Full record

SynthesisCanadian journal of anaesthesia = Journal canadien d'anesthesie2020

Probiotics in hospitalized adult patients: a systematic review of economic evaluations.

Vincent I Lau, Bram Rochwerg, Feng Xie, Jennie Johnstone, John Basmaji, Jana Balakumaran, Alla Iansavichene, Deborah J Cook

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Vincent I LauDepartment of Medicine, Division of Critical Care Medicine, Western University, London, ON, Canada. vinceissaclau@gmail.com.
Bram RochwergDepartment of Medicine, Division of Critical Care Medicine, McMaster University, Hamilton, ON, Canada.
Feng XieDepartment of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada.
Jennie JohnstonePublic Health Ontario, Toronto, ON, Canada.
John BasmajiDepartment of Medicine, Division of Critical Care Medicine, Western University, London, ON, Canada.
Jana BalakumaranMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Alla IansavicheneLibrary Services, London Health Sciences Center, London, ON, Canada.
Deborah J CookDepartment of Medicine, Division of Critical Care Medicine, McMaster University, Hamilton, ON, Canada.
McMaster University · CAWestern University · CAImpact · CALondon Health Sciences Centre · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProbiotics may prevent healthcare-associated infections, such as ventilator-associated pneumonia, Clostridioides difficile-associated diarrhea, and other adverse outcomes. Despite their potential benefits, there are no summative data examining the cost-effectiveness of probiotics in hospitalized patients. This systematic review summarized studies evaluating the economic impact of using probiotics in hospitalized adult patients.

methodsWe searched MEDLINE, EMBASE, CENTRAL, ACP Journal Club, and other EBM reviews (inception to January 31, 2019) for health economics evaluations examining the use of probiotics in hospitalized adults. Independently and in duplicate, we extracted data study characteristics, risk of bias, effectiveness and total costs (medications, diagnostics/procedures, devices, personnel, hospital) associated with healthcare-associated infections (ventilator-associated pneumonia, Clostridioides difficile-associated diarrhea and antibiotic-associated diarrhea). We used Grading of Recommendations Assessment, Development and Evaluation methods to assess certainty in the overall cost-effectiveness evidence.

resultsOf 721 citations identified, we included seven studies. For the clinical outcomes of interest, there was one randomized-controlled trial (RCT)-based health economic evaluation, and six model-based health economic evaluations. Probiotics showed favourable cost-effectiveness in six of seven (86%) economic evaluations. Three of the seven studies were manufacturer-supported, all which suggested cost-effectiveness. Certainty of cost-effectiveness evidence was very low because of risk of bias, imprecision, and inconsistency.

conclusionProbiotics may be an economically attractive intervention for preventing ventilator-associated pneumonia, Clostridioides difficile-associated diarrhea, and antibiotic-associated diarrhea in hospitalized adult patients. Nevertheless, certainty about their cost-effectiveness evidence is very low. Future RCTs examining probiotics should incorporate cost data to inform bedside practice, clinical guidelines, and healthcare policy.

trial registrationPROSPERO CRD42019129929; Registered 25 April, 2019.

Indexed as

Cross InfectionProbioticsAdultClostridium InfectionsCost-Benefit AnalysisDiarrheaHumansInpatientsPneumonia, Ventilator-Associated

Identifiers

PMID31721100
PMCPMC7222908
OpenAlexW2982801222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.